Safety and efficacy of insulin degludec/insulin aspart with bolus mealtime insulin aspart compared with standard basal-bolus treatment in people with Type 1 diabetes: 1-year results from a randomized clinical trial (BOOST® T1)

Comparison of Insulin Degludec/Insulin Aspart and Biphasic Insulin Aspart 30 in Uncontrolled, Insulin-Treated Type 2 Diabetes: A Phase 3a, Randomized, Treat-to-Target Trial

(2014) Gregory R. Fulcher et al.   DIABETES CARE

Efficacy and safety of insulin degludec given as part of basal-bolus treatment with mealtime insulin aspart in type 1 diabetes: a 26-week randomized, open-label, treat-to-target non-inferiority trial

(2014) M. J. Davies et al.   DIABETES OBESITY & METABOLISM

A nine country study of the burden of non-severe nocturnal hypoglycaemic events on diabetes management and daily function

(2013) M. Brod et al.   DIABETES OBESITY & METABOLISM

Superior glycaemic control with once-daily insulin degludec/insulin aspart versus insulin glargine in Japanese adults with type 2 diabetes inadequately controlled with oral drugs: a randomized, controlled phase 3 trial

(2013) Y. Onishi et al.   DIABETES OBESITY & METABOLISM

Insulin degludec improves glycaemic control with lower nocturnal hypoglycaemia risk than insulin glargine in basal-bolus treatment with mealtime insulin aspart in Type 1 diabetes (BEGIN®Basal-Bolus Type 1): 2-year results of a randomized clinical trial

(2013) B. W. Bode et al.   DIABETIC MEDICINE

Severe Hypoglycemia and Diabetic Ketoacidosis in Adults With Type 1 Diabetes: Results From the T1D Exchange Clinic Registry

(2013) Ruth S. Weinstock et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Insulin Degludec/Insulin Aspart Administered Once Daily at Any Meal, With Insulin Aspart at Other Meals Versus a Standard Basal-Bolus Regimen in Patients With Type 1 Diabetes: A 26-week, phase 3, randomized, open-label, treat-to-target trial

(2012) I. B. Hirsch et al.   DIABETES CARE

The Alteration of Aspart Insulin Pharmacodynamics When Mixed With Detemir Insulin

(2012) E. Cengiz et al.   DIABETES CARE

Insulin degludec: four times lower pharmacodynamic variability than insulin glargine under steady-state conditions in type 1 diabetes

(2012) T. Heise et al.   DIABETES OBESITY & METABOLISM

Ten Years of Experience with Biphasic Insulin Aspart 30

(2012) Andreas Liebl et al.   DRUGS

Comparison of a soluble co-formulation of insulin degludec/insulin aspart vs biphasic insulin aspart 30 in type 2 diabetes: a randomised trial

(2012) Leo Niskanen et al.   EUROPEAN JOURNAL OF ENDOCRINOLOGY

Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-Bolus Type 1): a phase 3, randomised, open-label, treat-to-target non-inferiority trial

(2012) Simon Heller et al.   LANCET

Design of the Novel Protraction Mechanism of Insulin Degludec, an Ultra-long-Acting Basal Insulin

(2012) Ib Jonassen et al.   PHARMACEUTICAL RESEARCH

A New-Generation Ultra-Long-Acting Basal Insulin With a Bolus Boost Compared With Insulin Glargine in Insulin-Naive People With Type 2 Diabetes: A randomized, controlled trial

(2011) T. Heise et al.   DIABETES CARE

Correlates of Insulin Injection Omission

(2010) M. Peyrot et al.   DIABETES CARE

Differences between long-acting insulins for the treatment of type 2 diabetes

(2010) Michael Gejl Jensen et al.   EXPERT OPINION ON PHARMACOTHERAPY